<DOC>
	<DOCNO>NCT01079806</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy entecavir pediatric patient chronic hepatitis B virus infection</brief_summary>
	<brief_title>A Phase III Study Safety Efficacy Entecavir Pediatric Patients With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Key Inclusion Criteria Males female , age 2 &lt; 18 year Hepatitis B surface antigenpositive Detectable hepatitis B e ( HBe ) antigen , detectable antiHBe antibody Alanine aminotransferase ( ALT ) 1.5 &lt; 10 time upper limit normal screen within 8 24 week prior screen Evidence presence hepatitis B virus DNA least 4 week screen &gt; 100,000 copies/mL screen Key Exclusion Criteria Any prior therapy entecavir At least 12 week prior therapy nucleoside nucleotide antiviral agent Therapy interferon alpha , thymosin alpha , nucleototide antiviral agent within 24 week screen Coinfection HIV , hepatitis C virus , hepatitis D virus Decompensated liver disease Liver transplant recipients Other form acute chronic condition may cause increase ALT level Children breastfed mother receive lamivudine whose mother receive lamivudine pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>